low - Pre-revenue biotech with minimal direct GDP linkage. Clinical trial timelines and regulatory processes operate independently of economic cycles. However, severe recessions can impact: (1) capital markets access for future financing rounds, (2) healthcare system capacity to enroll clinical trials, (3) payer willingness to reimburse ultra-high-cost genetic medicines. Patient populations (rare genetic diseases) remain stable regardless of economic conditions.

Rising interest rates create moderate headwinds through multiple channels: (1) higher discount rates compress NPV of distant future cash flows (first revenues likely 2028+), disproportionately impacting long-duration growth assets, (2) increased opportunity cost makes speculative biotech less attractive versus risk-free Treasuries, (3) tighter financial conditions reduce availability and increase cost of future equity/debt financing needed to fund operations through commercialization. Company's $800M cash position provides near-term insulation but eventual need for capital makes rate environment material. Conversely, rate cuts improve valuation multiples and financing conditions.

growth - Attracts speculative biotech investors seeking asymmetric returns from platform technology with multiple shots on goal. Appeals to thematic gene editing investors betting on sector transformation. Institutional ownership includes specialized healthcare funds and venture capital crossover investors. Not suitable for value or income investors given negative cash flows and no dividend. Recent 61% six-month rally suggests momentum traders participating on clinical optimism.